Spaëth D et al. - In a trial to provide further clinical evidence for the efficacy and safety of epoetinβ once weekly across a wide range of cancer types, it was shown that epoetinβ 30,000 IU once weekly effectively increases Hb levels, is well tolerated, and has similar efficacy in anemic pts with solid tumors or non-myeloid hematological malignancies Methods
This study involved pts with either a solid tumor or non-myeloid hematological malignancy, receiving or scheduled to receive further chemotherapy
Pts received epoetinβ 30,000 IU subcutaneously once weekly for 16 weeks
The primary efficacy endpoint was the change in hemoglobin (Hb) level according to the pt's baseline Hb level
Results
691 pts were included in the intent-to-treat population
Epoetin effectively increased Hb levels
Hb response was achieved in 60.4% of all pts and 61.2% of those with baseline Hb <11 g/dl
Hb response was similar in pts with solid tumors (60.5%) and non-myeloid hematological malignancies (60.2%)
Type of chemotherapy and baseline platelet count were independent predictive factors for response
See all
